Endocrine Abstracts

Methylglyoxal (MG) damages arginine protein residues, inhibits enzymes, disrupts insulin signal transmission, and plays a key role in the development of insulin resistance and hyperglycemia. High glucose levels cause an increase in glycation and methylglyoxal formation. Glycation is the main cause of protein damage, leading to the production of free radicals and causing inflammation.

The purpose of the study: To Identify the relationship of methylglyoxal content with markers of inflammation (retinol–binding protein). The lipid peroxidation level was determined by the content of malondialdehyde (MDA). Determine the level of MG content by high–performance liquid chromatography.

Materials and methods: 208 patients with NAFLD and type 2 diabetes were examined. There were 76 patients with type 2 diabetes and 132 with impaired glucose tolerance (NTG). The average age is 57.3 ± 5.2 years. BMI34, 85 ± 1.79. In 30 patients conducted hypoglycemic therapy with a medication Formiga (of dapagliflozin).

Research results: In 30 patients with NAFLD and DM, the serum MG content of 520.75 ± 114.35 nm/l was 283.3 ± 11.5 nm/l, in the control group of 251.3 ± 53.6 nm/l.

Retinol–binding protein as a marker of type I and type 2 diabetes in this group of patients was increased and amounted to 55.83 ± 2.92 mg/l compared to the control group of 26.15 ± 1.31 mg/l (P = 0.001). Hyperglycemia increases the processes of lipid peroxidation. MG and MDA are correlated (r = 0.495).

Conclusions: Glucose–lowering therapy with a medication Forsiga leads to a decrease in the level of hyperglycemia, the level of MG and processes of lipid peroxidation.

MDA up to 24.12 + 1.64 mmol/l p/l 16.9 + 3.86.

MGL 192.11 + 16.34 nm/l